Get the Stockscreener App
4.40
0.45%
-0.02
After Hours:
4.40
Inmune Bio Inc stock is traded at $4.40, with a volume of 394.91K.
It is down -0.45% in the last 24 hours and down -3.51% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$4.42
Open:
$4.36
24h Volume:
394.91K
Relative Volume:
1.69
Market Cap:
$97.56M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-2.8947
EPS:
-1.52
Net Cash Flow:
$-11.98M
1W Performance:
-7.37%
1M Performance:
-3.51%
6M Performance:
-42.86%
1Y Performance:
-55.73%
1-Day Range:
$4.32
$4.60
1-Week Range:
$4.32
$5.16
52-Week Range:
$4.32
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
4.40 | 97.56M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Charles Schwab Investment Management Inc. Trims Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio stock hits 52-week low at $4.44 amid market challenges - Investing.com Canada
INmune Bio stock hits 52-week low at $4.44 amid market challenges By Investing.com - Investing.com South Africa
Institutions along with retail investors who hold considerable shares inINmune Bio, Inc. (NASDAQ:INMB) come under pressure; lose 11% of holdings value - Simply Wall St
Learn to Evaluate (INMB) using the Charts - Stock Traders Daily
INmune Bio extends rights agreement to 2025 - Investing.com India
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times
INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan
INmune Bio extends rights agreement to 2025 By Investing.com - Investing.com Nigeria
Inmune Bio Announces Stock Options and Leadership Changes - TipRanks
OmniScience and INmune Bio Partner for Alzheimer’s Trial - Yahoo Finance
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate - GlobeNewswire
INmune Bio Partners with OmniScience, Deploys GenAI Platform for Landmark Alzheimer's Trial - StockTitan
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc.. - Marketscreener.com
INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – Should You Buy? - Defense World
INmune Bio (NASDAQ:INMB) Trading 1.7% HigherWhat's Next? - MarketBeat
Scotiabank Initiates Coverage of INmune Bio (INMB) with Sector Outperform Recommendation - MSN
INmune Bio stock hits 52-week low at $4.76 amid market challenges - Investing.com
(INMB) Trading Report - Stock Traders Daily
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease - Marketscreener.com
INmune Bio Hits Major Milestone: 208 Patients Enrolled in Phase 2 Alzheimer's Trial | INMB Stock News - StockTitan
Inmune Bio Emerges as Biotech Innovator in 2023 - TipRanks
INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript - MSN
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance UK
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Earnings call: INmune Bio Q3 2024 results show progress in clinical trials - Investing.com
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update - The Manila Times
Inmune Bio Reports Increased Losses Amid Financing Efforts - TipRanks
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
INmune Bio Q3 2024 Earnings Preview - MSN
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6% - MarketBeat
INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB - The Manila Times
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance
INmune Bio (INMB) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
INmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System Diseases - MarketWatch
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination - The Manila Times
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 - The Manila Times
Insider Stock Buying Reaches US$951.2k On INmune Bio - Yahoo Finance
Alliance Global Partners Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World
(INMB) Technical Data - Stock Traders Daily
INmune Bio stock hits 52-week low at $4.8 amid market challenges - Investing.com
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Decrease in Short Interest - MarketBeat
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
| Juda Scott | Director |
Jun 25 '24 |
Buy |
7.27 |
5,000 |
36,350 |
71,603 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):